Fenwick Represents Corium in $52 Million Follow-On Public Offering

Fenwick & West represented Corium International, Inc. (NASDAQ: CORI), a biopharmaceutical company focused on the development of advanced transdermal drug delivery technologies and products, in its $52 million follow-on public offering. The company priced 4,000,000 shares of its common stock at a price to the public of $13.00 per share. In addition, Corium has granted the underwriters a 30-day option to purchase up to an additional 600,000 shares of its common stock.

Jefferies LLC and Leerink Partners LLC acted as joint book-running managers for the offering. Needham & Company and FBR Capital Markets & Co. acted as co-managers.

The Fenwick transaction team included corporate attorneys Robert Freedman, Dawn Belt, Lara Foster and Debbie Li.